Tarsus Pharmaceuticals, Inc. (TARS) Balance Sheet

The reported equity build through 2025 appears driven by capital raises and retained losses narrowing from -$360.2M to -$426.6M, though the deficit still grew in absolute terms. The sharp 2026Q3 drop to $104.0M alongside a retained earnings figure of -$1.1B suggests a large loss or reclassification event that warrants further investigation rather than a simple continuation of the trend. Investors should monitor whether the 2026Q3 figures reflect a true economic deterioration or a reporting discontinuity.

The compression of the current ratio from above 5x through 2025 toward 2x in 2026Q3 reflects both rising current liabilities and the cash deployment visible in the acquisition outflow. Cash of $136.5M against total liabilities of $401.5M suggests the buffer is serviceable but thinner than in prior periods. Investors should monitor whether cash position stabilizes as operating cash flow matures.

Debt has been essentially flat at roughly $72M to $94M across the ten quarters, indicating the leverage movement is mechanical rather than strategic. The 0.85 D/E in 2026Q3 reflects a shrinking equity base instead of increased obligations, which may indicate a higher risk profile even without new debt. Refinancing risk appears contained given stable principal, but the equity-driven leverage spike warrants monitoring.

The low PPE base is consistent with a single-product commercial pharma model that outsources manufacturing, supporting the high gross margins noted in prior analysis. Goodwill rose from $3.7M to $16.6M across the period, reflecting acquisition activity that may carry impairment risk if commercial performance falters. Investors should watch the goodwill balance relative to acquired revenue contribution.